On September 17, 2020 Zai Lab of Shanghaireported that it is conducting a Hong Kong IPO that is expected to raise $845 million, based on the price of the company’s US-listed shares. On the NASDAQ Exchange, Zai has a market capitalization of $6.2 billion (Press release, Zai Laboratory, SEP 17, 2020, View Source [SID1234565349]). The company is developing a large portfolio of in-licensed cancer and infectious disease candidates. Its PARP inhibitor is approved for China use in ovarian cancer and a medical device, Tumor Treating Fields, is approved in China for glioblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!